Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wang-jun Liao

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University|February 28, 2009
[Clinical significance of VEGF levels in serums of colorectal cancer patients at stage IV]Na Huang, Lin Yang, Meng-ran Cao, et al.
Di 1 Jun Yi Da Xue Xue Bao = Academic Journal of the First Medical College of PLA|October 23, 2002
[Investigation of short-term therapy results for radiofrequency ablation by positron emission tomography]Wang-Jun Liao, Rong-Cheng Luo, Shi-Jun Kang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 6, 2010
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patientsRui Feng Xu, Ji Ping Sun, Shi Rong Zhang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|December 3, 2010
[Evaluation of tumor angiogenesis using microbubbles conjugated with RGD peptides and contrast enhanced ultrasound]Guang-quan Hu, Li Yang, Yun-bin Xiao, et al.
American Journal of Cancer Research|October 12, 2020
Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm studyFeng Wang, Tian-Shu Liu, Xiang-Lin Yuan, et al.
Journal of Hematology & Oncology|November 29, 2024
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib studyDan-Yun Ruan, Xiao-Li Wei, Fu-Rong Liu, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University|February 28, 2009
[Clinical significance of VEGF levels in serums of colorectal cancer patients at stage IV]Na Huang, Lin Yang, Meng-ran Cao, et al.
Di 1 Jun Yi Da Xue Xue Bao = Academic Journal of the First Medical College of PLA|October 23, 2002
[Investigation of short-term therapy results for radiofrequency ablation by positron emission tomography]Wang-Jun Liao, Rong-Cheng Luo, Shi-Jun Kang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 6, 2010
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patientsRui Feng Xu, Ji Ping Sun, Shi Rong Zhang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|December 3, 2010
[Evaluation of tumor angiogenesis using microbubbles conjugated with RGD peptides and contrast enhanced ultrasound]Guang-quan Hu, Li Yang, Yun-bin Xiao, et al.
American Journal of Cancer Research|October 12, 2020
Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm studyFeng Wang, Tian-Shu Liu, Xiang-Lin Yuan, et al.
Journal of Hematology & Oncology|November 29, 2024
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib studyDan-Yun Ruan, Xiao-Li Wei, Fu-Rong Liu, et al.
Pageof 3